NCT02639026 2025-11-25
Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
Clinical Trials
19 trialsNCT03693612 2024-08-28
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
GlaxoSmithKline
Phase 1/2 Completed
NCT00378482 2024-08-22
A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.
AstraZeneca
Phase 2 Completed
NCT05928962 2023-07-10
An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanomas
Fujian Cancer Hospital
Phase 1 Unknown
NCT04107168 2023-02-16
Microbiome Immunotherapy Toxicity and Response Evaluation
Cambridge University Hospitals NHS Foundation Trust
Unknown
NCT02643303 2022-12-02
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT04223648 2021-11-22
Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma
Yale University
Phase EARLY_PHASE1 Withdrawn
NCT00471887 2020-10-26
Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT01103635 2020-04-07
Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT04274816 2020-02-18
Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma
Amsterdam UMC, location VUmc
Phase 1 Completed
NCT02586987 2019-11-18
A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Completed
NCT01034787 2017-10-27
Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma
AHS Cancer Control Alberta
Phase 2 Completed
NCT00610857 2017-06-22
Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma
University of Pittsburgh
Phase 2 Completed
NCT00897312 2016-04-25
Effect of Biological Therapy on Biomarkers in Patients With Untreated Hepatitis C, Metastatic Melanoma, or Crohn Disease
Vanderbilt-Ingram Cancer Center
Terminated
NCT00257205 2012-07-02
CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy
AstraZeneca
Phase 3 Completed
NCT00254579 2012-06-07
Study of CP-675,206 in Refractory Melanoma
AstraZeneca
Phase 2 Completed
NCT00086489 2012-06-06
CP-675,206 In Patients With Advanced Melanoma
AstraZeneca
Phase 2 Completed
NCT00431275 2012-06-06
Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody
AstraZeneca
Phase 1 Completed
NCT00585000 2012-06-06
A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma
AstraZeneca
Phase 1 Terminated